Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375

15:02 EDT 14 Mar 2018 | BioPortfolio Report Blog

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst?

Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable or winning pharma any friends. In this expert report, US and EU payers note that monopolistic pricing for novel products that represent the only therapeutic option, or the high prices demanded for treatments with minimal therapeutic benefits, cannot always be afforded or justified. Moderate payers are looking to pharma to act, less moderate payers want government intervention and price controls. Pharma risks killing the goose that laid the golden egg and payers warn it's time to get real about cancer drug pricing if pharma wants widespread reimbursement and market access.

Discover on this page...

Why this report is important to you

What the report will enable you to do

Full report contents

Why this report is important to you

Oncological care is an area that has seen some of the steepest spending increases in the past two decades. In 2017, annual spending on anticancer drugs was approximately $100 billion globally, but this figure is predicted to rise to $150 billion by 2020. Some price rises have been triggered by the advent of a more sophisticated understanding of the pathophysiology of cancer, and more effective treatments mean that patients are often living longer and therefore spending on costly therapies puts pressure on the public and private purses. Payers recognise that some highcost hightechnology drugs provide profound patient improvement and, in the wider context of alternative interventions, make commercial sense. But therapies of minimal value, or products priced for rare cancers and then extended to common cancers, are facing mounting resistance. Pharma can no longer hide behind the claim that high prices are needed to pay for overall RD spend and investment many payers see price as driven by nothing more than profit. The ball is in pharma's court to respond and really prove the prices they want represent value.

This report will enable you to...

Understand the diverse pricing and reimbursement environments in the US, UK, France, Germany, Italy and Spain

Deliver the real world data that is supportive of payer decision making

Appraise payer attitudes to innovative contracting and know why payment by results is not universally popular

Know what factors payers would like to see considered when setting prices

Leverage the value biomarkers and companion diagnostics have in gaining payer support

Appreciate the positive influence on payers of headtohead clinical trial studies

Report Contents

Executive summary

Research methodology and objectives

Experts interviewed


Pricing and reimbursement in Europe and the US

Cancer drug spend

Pricing and reimbursement mechanisms

Key Insights

Determination of drug price and reimbursement status




Case study: Opdivo nivolumab



United Kingdom UK

Blueteq system in the UK

United States

Factors and evidence that play a role in demonstrating value in payer decisionmaking

Key Insights

Robust data: clinical trial and real world

Cost effectiveness evidence: Health Technology Assessment HTA

Biomarkers and companion diagnostics

Other factors that can influence pricing and reimbursement decisions

Involvement of payers during drug development


United States

Cost to patient: outofpocket USspecific

Common versus rare cancers


United States

Financing mechanisms for cancer drugs: payment by results and risksharing agreements

Key Insights

Payment by results


United States

Value for money with cancer therapies

Key Insights

Justifying the high cost of the newer cancer therapies

Prohibitively high cost cancer drugs: push back or payer acceptance

Pricing a cancer therapy: component parts

Pricing by drug company

Reimbursement decision by payer

High technology has driven price hikes

Patient benefit as a function of cost


Quality of life as a measure of effectiveness

Pricing of cancer drugs compared to other therapeutic areas

Improved patient support financial help programs

Formulating a cancer drug price: component parts

Drive for change in cancer pricing and reimbursement

Key Insights

Challenging high cancer drug prices

The substantial price hike in cancer therapy since 2000

Take home messages





United Kingdom

United States


Original Article: Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375


More From BioPortfolio on "Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...